Immix Biopharma Inc./$IMMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Ticker
$IMMX
Sector
Primary listing
Employees
20
Headquarters
Website
IMMX Metrics
BasicAdvanced
$63M
-
-$0.78
0.27
-
Price and volume
Market cap
$63M
Beta
0.27
52-week high
$3.20
52-week low
$1.34
Average daily volume
248K
Financial strength
Current ratio
1.231
Quick ratio
1.163
Long term debt to equity
20.897
Total debt to equity
22.411
Profitability
EBITDA (TTM)
-23.66
Effective tax rate (TTM)
-0.18%
Management effectiveness
Return on assets (TTM)
-66.85%
Return on equity (TTM)
-162.04%
Valuation
Price to book
13.37
Price to tangible book (TTM)
13.37
Price to free cash flow (TTM)
-4.82
Free cash flow yield (TTM)
-20.75%
Free cash flow per share (TTM)
-0.454
Growth
Earnings per share change (TTM)
-3.14%
3-year earnings per share growth (CAGR)
-35.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immix Biopharma Inc. stock?
Immix Biopharma Inc. (IMMX) has a market cap of $63M as of August 26, 2025.
What is the P/E ratio for Immix Biopharma Inc. stock?
The price to earnings (P/E) ratio for Immix Biopharma Inc. (IMMX) stock is 0 as of August 26, 2025.
Does Immix Biopharma Inc. stock pay dividends?
No, Immix Biopharma Inc. (IMMX) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next Immix Biopharma Inc. dividend payment date?
Immix Biopharma Inc. (IMMX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immix Biopharma Inc.?
Immix Biopharma Inc. (IMMX) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.